Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.35 per share a year ago.
Should You Buy Quest Diagnostics Ahead of Earnings?
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today
For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new solutions. Strong profit margins, proven cashflow and dividend growth, and investment-grade credit ratings from major agencies are additional upside factors.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
